169 related articles for article (PubMed ID: 35403278)
1. Inosine monophosphate dehydrogenase type1 sustains tumor growth in hepatocellular carcinoma.
Jia X; Liu Y; Cheng Y; Wang Y; Kang H; Ma Z; Chen K
J Clin Lab Anal; 2022 May; 36(5):e24416. PubMed ID: 35403278
[TBL] [Abstract][Full Text] [Related]
2. MYBL2 regulates de novo purine synthesis by transcriptionally activating IMPDH1 in hepatocellular carcinoma cells.
Zhao JZ; Wang W; Liu T; Zhang L; Lin DZ; Yao JY; Peng X; Jin G; Ma TT; Gao JB; Huang F; Nie J; Lv Q
BMC Cancer; 2022 Dec; 22(1):1290. PubMed ID: 36494680
[TBL] [Abstract][Full Text] [Related]
3. Different characteristics and nucleotide binding properties of inosine monophosphate dehydrogenase (IMPDH) isoforms.
Thomas EC; Gunter JH; Webster JA; Schieber NL; Oorschot V; Parton RG; Whitehead JP
PLoS One; 2012; 7(12):e51096. PubMed ID: 23236438
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of the mycophenolic acid targets inosine monophosphate dehydrogenases IMPDH1 and IMPDH2: gene sequence variation and functional genomics.
Wu TY; Peng Y; Pelleymounter LL; Moon I; Eckloff BW; Wieben ED; Yee VC; Weinshilboum RM
Br J Pharmacol; 2010 Dec; 161(7):1584-98. PubMed ID: 20718729
[TBL] [Abstract][Full Text] [Related]
5. IMPDH dysregulation in disease: a mini review.
Burrell AL; Kollman JM
Biochem Soc Trans; 2022 Feb; 50(1):71-82. PubMed ID: 35191957
[TBL] [Abstract][Full Text] [Related]
6. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma.
Liu C; Zhang W; Zhou X; Liu L
Front Immunol; 2022; 13():983490. PubMed ID: 36618420
[TBL] [Abstract][Full Text] [Related]
7. c-Myc-IMPDH1/2 axis promotes tumourigenesis by regulating GTP metabolic reprogramming.
Zhang Q; Cui K; Yang X; He Q; Yu J; Yang L; Yao G; Guo W; Luo Z; Liu Y; Chen Y; He Z; Lan P
Clin Transl Med; 2023 Jan; 13(1):e1164. PubMed ID: 36629054
[TBL] [Abstract][Full Text] [Related]
8. IMPDH1/YB-1 Positive Feedback Loop Assembles Cytoophidia and Represents a Therapeutic Target in Metastatic Tumors.
Ruan H; Song Z; Cao Q; Ni D; Xu T; Wang K; Bao L; Tong J; Xiao H; Xiao W; Cheng G; Xiong Z; Liang H; Liu D; Wang L; Olivier T; Jane BH; Yang H; Zhang X; Chen K
Mol Ther; 2020 May; 28(5):1299-1313. PubMed ID: 32209435
[TBL] [Abstract][Full Text] [Related]
9. LncRNA UCA1 Participates in De Novo Synthesis of Guanine Nucleotides in Bladder Cancer by Recruiting TWIST1 to Increase IMPDH1/2.
Liu SS; Li JS; Xue M; Wu WJ; Li X; Chen W
Int J Biol Sci; 2023; 19(8):2599-2612. PubMed ID: 37215997
[TBL] [Abstract][Full Text] [Related]
10. Retinal isoforms of inosine 5'-monophosphate dehydrogenase type 1 are poor nucleic acid binding proteins.
Xu D; Cobb G; Spellicy CJ; Bowne SJ; Daiger SP; Hedstrom L
Arch Biochem Biophys; 2008 Apr; 472(2):100-4. PubMed ID: 18295591
[TBL] [Abstract][Full Text] [Related]
11. Characterization of retinal inosine monophosphate dehydrogenase 1 in several mammalian species.
Spellicy CJ; Daiger SP; Sullivan LS; Zhu J; Liu Q; Pierce EA; Bowne SJ
Mol Vis; 2007 Oct; 13():1866-72. PubMed ID: 17960124
[TBL] [Abstract][Full Text] [Related]
12. IMPDH1 retinal variants control filament architecture to tune allosteric regulation.
Burrell AL; Nie C; Said M; Simonet JC; Fernández-Justel D; Johnson MC; Quispe J; Buey RM; Peterson JR; Kollman JM
Nat Struct Mol Biol; 2022 Jan; 29(1):47-58. PubMed ID: 35013599
[TBL] [Abstract][Full Text] [Related]
13. On the molecular pathology of neurodegeneration in IMPDH1-based retinitis pigmentosa.
Aherne A; Kennan A; Kenna PF; McNally N; Lloyd DG; Alberts IL; Kiang AS; Humphries MM; Ayuso C; Engel PC; Gu JJ; Mitchell BS; Farrar GJ; Humphries P
Hum Mol Genet; 2004 Mar; 13(6):641-50. PubMed ID: 14981049
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of inosine monophosphate dehydrogenase activity and expression during the early period of mycophenolate mofetil therapy in de novo renal transplant patients.
Molinaro M; Chiarelli LR; Biancone L; Castagneto M; Boschiero L; Pisani F; Sabbatini M; Sandrini S; Arbustini E; Tinelli C; Regazzi M; Schena FP; Segoloni GP
Drug Metab Pharmacokinet; 2013; 28(2):109-17. PubMed ID: 22892445
[TBL] [Abstract][Full Text] [Related]
15. Disease Progression in Patients with Autosomal Dominant Retinitis Pigmentosa due to a Mutation in Inosine Monophosphate Dehydrogenase 1 (IMPDH1).
Bennett LD; Klein M; John FT; Radojevic B; Jones K; Birch DG
Transl Vis Sci Technol; 2020 Apr; 9(5):14. PubMed ID: 32821486
[TBL] [Abstract][Full Text] [Related]
16. Highly selective inhibition of IMPDH2 provides the basis of antineuroinflammation therapy.
Liao LX; Song XM; Wang LC; Lv HN; Chen JF; Liu D; Fu G; Zhao MB; Jiang Y; Zeng KW; Tu PF
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5986-E5994. PubMed ID: 28674004
[TBL] [Abstract][Full Text] [Related]
17. T cell activation triggers reversible inosine-5'-monophosphate dehydrogenase assembly.
Duong-Ly KC; Kuo YM; Johnson MC; Cote JM; Kollman JM; Soboloff J; Rall GF; Andrews AJ; Peterson JR
J Cell Sci; 2018 Sep; 131(17):. PubMed ID: 30154209
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic benefit derived from RNAi-mediated ablation of IMPDH1 transcripts in a murine model of autosomal dominant retinitis pigmentosa (RP10).
Tam LC; Kiang AS; Kennan A; Kenna PF; Chadderton N; Ader M; Palfi A; Aherne A; Ayuso C; Campbell M; Reynolds A; McKee A; Humphries MM; Farrar GJ; Humphries P
Hum Mol Genet; 2008 Jul; 17(14):2084-100. PubMed ID: 18385099
[TBL] [Abstract][Full Text] [Related]
19. Terminal Peptide Extensions Augment the Retinal IMPDH1 Catalytic Activity and Attenuate the ATP-induced Fibrillation Events.
Andashti B; Yazdanparast R; Motahar M; Barzegari E; Galehdari H
Cell Biochem Biophys; 2021 Jun; 79(2):221-229. PubMed ID: 33733369
[TBL] [Abstract][Full Text] [Related]
20. Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression.
Bremer S; Mandla R; Vethe NT; Rasmussen I; Rootwelt H; Line PD; Midtvedt K; Bergan S
Transplantation; 2008 Jan; 85(1):55-61. PubMed ID: 18192912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
